Introduction:

Diabetes mellitus is a common chronic disease. 50% of nontraumatic amputations of the lower limb occur in diabetic patients and 85% of these amputations are preceded by a diabetic foot injury.

Objective:

To describe the outcomes of Heberprot-P® usage in diabetic foot ulcers.

Methods:

A descriptive, cross-sectional study was carried out at Ramón López Peña Polyclinic in Santiago de Cuba, from January to December 2015. The study population consisted of 19 patients diagnosed with diabetic foot ulcer and who were administered intralesional Heberprot-P®. The variables studied were sex, age, type of diabetes, classification of the lesions according to Wargner, treatment dose, affected member and location, adverse reactions and treatment outcome.

Results:

Patients between 50 and 59 years of age (36.84%) and female participants (52.60%) predominated. The lesions treated were Wagner II, with prevalence of type 2 diabetes; depending on the location, the hallux accounted for 36.83%. 31.57% of patients were administered up to five doses of treatment. The lower left limb was the most affected (68.39%) and 89.48% of the patients had total closure.

Conclusions:

For the context of the usual clinical practice and for the evolution of patients treated with Heberprot-P®, this product continues to be a safe and effective medication in the treatment of diabetic foot ulcers. The use of this medicine should not be seen as an isolated therapy, but as part of a prevention strategy designed to reduce the effect of modifiable risk factors in diabetic patients.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )